74 results about "Marker Antigens" patented technology

The invention relates to a chemiluminescent immunoassay method, in particular to a method for analyzing an acridine ester labeled antigen or an acridine ester labeled antibody and an immunoassay kit prepared by same. An acridine ester label is provided with a special luminescent group in a chemical structure, and the special group directly participates in luminescent reaction in the analyzing process of luminescent immunization; the substance does not have background luminescence usually, can be used for detecting a sample with low concentration or trace concentration in the reaction and is a luminescent agent with high luminescent efficiency; and molecules of acridine ester I and acridine ester II and acridine amide III can be combined with an antibody (antigen) to generate the labeled antibody with high chemiluminescent activity and immunological reaction specificity.

An immuno-chromatographic detection device for detecting an analyte in sample, such as estrogen in a urine or saliva sample, the device comprising (a) a binding membrane having immobilized thereon (i) an test antibody against said analyte in at least one detection region, and (ii) a control antibody against a control antigen known to be present in the sample in a control region, (b) a sample membrane located at a first end of the binding membrane for receiving the sample, wherein the sample membrane is in chromatographic connection with the binding membrane, and (c) a label membrane containing (iii) a labeled antigen that is capable of binding to the test antibody and upon binding with the test antibody exhibits an observable change at the at least one detection region, and (iv) a labeled control antigen that is capable of binding to the control antibody and upon binding with the control antibody exhibits an observable change at the control region, wherein the sample membrane is separated from the label membrane by a waterproof membrane which is removable to allow the sample membrane and label membrane to be connected chromatographically. Also provided are kits comprising the device, method for detecting the analyte, and methods for manufacturing the device and kit.

The invention provides a composite nano colloidal gold chitosan immune carrier, wherein, colloidal gold is uniformly dispersed in chitosan. The invention also provides a preparation method of the composite nano colloidal gold chitosan immune carrier and a labeled antigen-antibody. According to the invention, the characteristic that chitosan has good affinity for the antigen and antibody is applied in the colloidal gold, thus the adsorption capability of the colloidal gold for the antigen-antibody is increased, and the amount of the colloidal gold is reduced. The composite nano colloidal gold chitosan immune carrier can be widely used for immunodetection or immunodiagnosis in the fields of biomedicine or agriculture and the like.

The invention discloses an ELISA (Enzyme-Linked Immunosorbent Assay) kit for detecting a polypeptide marker antigen. The kit contains a monoclonal antibody of the polypeptide marker antigen; and the monoclonal antibody is secreted by a hybridoma cell strain CGMCC No.5269 of a polypeptide marker monoclonal antibody capable of resisting primary liver cancer. The invention also provides a method for detecting the polypeptide marker antigen. The monoclonal antibody provided by the invention has the advantage of strong specificity aiming at the polypeptide marker antigen; and the method for detecting the polypeptide marker antigen is simple, convenient and rapid in operation step and beneficial to clinical detection, and can be used for carrying out high-flux and low-cost detection of an enzyme linked detector.

The invention discloses a high-sensitivity enzyme-linked immunoassay method. The method comprises the following steps of: according to a characteristic of specific binding of a measured object and an antibody (antigen), marking the antigen or the antibody and the corresponding antibody or antigen by a corresponding enzyme under a specific condition so as to achieve an absorption combination process, and indirectly representing the concentration of the measured object by the catalytic speed of the marked enzyme about a substrate. According to the high-sensitivity enzyme-linked immunoassay method provided by the invention, a problem of insufficient sensitivity of a regular enzyme-linked immunoassay based on a spectrophotometry is effectively overcome, and the high-sensitivity chemical oscillation dynamics detection and enzymatic dynamics analysis with specificity and flexibility amplification action are combined by utilizing an antibody-antigen specificity combination principle, so that the problems of low chemical oscillation selectivity and incapability of carrying out qualitative determination are overcome, thus the chemical oscillation in combination with the enzyme-linked immunoassay method can be used for qualitative and quantitative determination of substances such as medicine and pesticide micromolecules, antibody, antigen, specific protein, nucleic acid, disease factors and the like.

The present invention provides a method of selecting an antibody against a target substance to be measured which comprises selecting the antibody against the target substance by antigen-antibody reaction in the presence of a substance interfering with the antigen-antibody reaction. That is, an antigen and a labeled antigen are reacted with the antibody in the presence of an interfering substance such as an environment pollutant, and on the basis of the degree of reaction thereof, the antibody against the target substance highly resistant to the interfering substance is selected. Thereby, even if a test sample is contaminated with a substance interfering with antigen-antibody reaction, the antibody highly resistant to a substance interfering with antigen-antibody reaction is not influenced by the interfering substance and gives a correct value in the quantification.

The invention discloses an aftosa totivirus particle vaccine composition as well as a preparation method and an application thereof. The aftosa totivirus particle vaccine composition disclosed by the invention contains totivirus particles of aftosa virus and a stable cryoprotectant, wherein the stable cryoprotectant is composed of the following matters: polyhydric alcohol, a buffer solution and a nonionic surfactant. The stable cryoprotectant provided by the invention stabilizes the vaccine antigen, protects the titer and the effect of the marker vaccine, protects the antigen stability of the marker vaccine or the antigen stability of the marker antigen library in a production process and a cold chain process, and can maintain the titer or the activity of the marker vaccine for a longer time under liquid and refrigeration conditions.

The invention provides an immuno-mass spectrometric detection kit for an esophagus cancer. The detection kit contains a monoclonal antibody secreted by a hybridoma cell strain of which the preservation number is CGMCC No. 5269, and a solid-phase carrier; and the monoclonal antibody is fixed on the solid-phase carrier. The monoclonal antibody related to the detection kit has strong binding specificity aiming at peptide marker antigens. Detection with high flux, high sensitivity and high accuracy of the esophagus cancer can be achieved by the combination of immunization and a mass-spectrometric technique. In addition, the immuno-mass spectrometric detection kit belongs to the technology of diagnosis of molecular level, and is simpler in operation and lower in cost compared with tumor iconography.

The invention discloses protein capable of specifically detecting mycobacterium tuberculosis infection, and provides application of Rv1438 protein to preparation of products for detecting or assisting in detecting mycobacterium tuberculosis. The experiment of the invention proves that mycobacterium tuberculosis-derived protein segments are screened, a mycobacterium tuberculosis marker antigen RV1438 for detecting tuberculosis is provided, and the antigen is used for in vitro detecting specific T cell immunoreaction to serve as a reference for diagnosing patients suffering from tuberculosis and can be used for diagnosing whether the patients are infected with the mycobacterium tuberculosis. The protein can be used for detecting mycobacterium tuberculosis infection, and the specificity reaches 70% at present.

The present invention relates to a method of detecting liver cancer in a mammalian subject by detecting an antibody in a test sample comprising a bodily fluid from the mammalian subject, wherein the antibody is an autoantibody immunologically specific for a tumour marker protein selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B, which method comprises contacting the test sample with a tumour marker antigen selected from the group consisting of MMP9, AIF1, EpCAM and CDKN1B and determining the presence or absence of complexes of the tumour marker antigen bound to autoantibodiespresent in the test sample where the presence of said complexes is indicative of the presence of liver cancer. Also included within the invention are corresponding methods of diagnosing and treating liver cancer in a mammalian subject, corresponding methods of predicting response to an anti-liver cancer treatment, a corresponding method of detecting an antibody in a test sample comprising a bodilyfluid from a mammalian subject and kits suitable for performing methods of the invention.

The invention relates to a hepatocirrhosis immuno-mass spectrometric detection reagent kit, which comprises a monoclonal antibody and a solid carrier, which are secreted by Hybridoma cell strain with a preserving number of CGMCC No.5269. The monoclonal antibody has strong specificity for polypeptide marker antigens; and by adopting the immunity technology to be combined with the mass spectrum technology, high flux, high sensitivity and high precision on detecting the hepatocirrhosis can be realized, so an early warning effect on the liver cancer can be better played. In addition, the reagent kit belongs to the diagnosis in molecular level, so the early warning capacity is stronger compared with the tumor imaging, and the cost is low.

The invention relates to an immune colloidal gold test strip and a detection method for karyotype polyhedrosis viruses of bombyx mori, particularly relates to an immune colloidal gold diagnosis test strip for detecting the karyotype polyhedrosis viruses of the bombyx mori by adopting an immunochromatography technology, and a preparation method of the immune colloidal gold diagnosis test strip, and belongs to the technical field of virus epidemic disease diagnosis. The immune colloidal gold test strip comprises a colloidal gold pad marked with an antigen BmNPV-Lef4 antibody and a coated nitrocellulose membrane, wherein an upper detection line of the nitrocellulose membrane is coated by rabbit-anti BmNPV-Lef4; and a quality control line at the lower part of the nitrocellulose membrane is coated with goat-anti-mouse IgG. The immune colloidal gold test strip is used for detecting the karyotype polyhedrosis viruses of the bombyx mori; compared with a traditional colloidal gold detection method, a double-antibody sandwich method is adopted when the colloidal gold test strip is prepared and a concentration proportion of two virus antibodies is regulated, so that the specificity, the sensitivity and the stability of a detection result can be effectively guaranteed; the detection sensitivity is high and the detection method is simple and convenient and is applied to the detection of the karyotype polyhedrosis viruses of the bombyx mori for the first time.

The invention relates to the technical field of micro-fluidic chip ELISA detection, in particular to a micro-fluidic chip for detecting multiple infection markers in peripheral blood through multi-channel ELISA. The micro-fluidic chip comprises a substrate, a sample adding pool, a capillary channel and a detection area. A serum sample is fed into the sample adding pool through a blood sampling port, driving is carried out through ultrasonic waves, infection marker antigen molecules in a serum sample enter the detection area through the capillary channel, and the infection marker antigen molecules in the serum sample are captured by infection marker antibodies of enzyme-linked immunosorbent assay in the reaction tank; full-automatic chip detection is realized by using an ELISA detection micro-fluidic chip technology, and human interference is not needed; and the detection repeatability of the same sample is high, and the detection result has high stability and reliability.